Innovate UK is a non-departmental public body established in 2007 and based in Swindon, United Kingdom. Funded by a government grant, it supports innovation in science and technology by providing funding services to businesses across various sectors and regions. The organization aims to drive productivity and economic growth by facilitating advancements that contribute to the UK’s economic landscape. In addition to funding, Innovate UK offers a range of services and information related to business and economic development, thereby fostering a supportive environment for innovation.
Programme Director of Industrial Strategy Challenge Fund
Will Drury
Executive Director, Digital and Technologies
Paul Gadd
Deputy Director
Dr. Tom Jenkins
Deputy Director
Scott James O'Brien
Director, Innovation Finance
Nigel Walker
Deputy Director, Lending and Investor Partnerships
Dave Wilkes
Director of Innovation Ecosystem
Past deals in Healthcare
StimOxyGen
Grant in 2025
StimOxyGen is a biotechnology company focused on developing innovative, pH-responsive nanoparticles. These nanoparticles are designed to generate oxygen in hypoxic tumors, enhancing the effectiveness of cancer treatments like radiotherapy and chemotherapy. The company's core technology involves a nanoparticle formulation that dissolves in the low pH environment of tumors, transiently producing oxygen to fuel tumors and maximize the therapeutic effects of radiotherapy.
Linkgevity
Grant in 2025
LinkGevity is a biotechnology company specializing in drug discovery, with a focus on longevity and age-related diseases. It operates an AI-powered platform designed to expedite the development of life-saving medications. By combining AI and pharmaceutical expertise, the company analyzes extensive datasets to predict and identify promising drug candidates, aiming to extend healthy lifespan and bring innovative treatments to market more swiftly.
Lant Medical
Grant in 2025
Lant Medical is a health technology company specializing in the development of non-antibiotic treatments for Helicobacter pylori (H. pylori) infections. Their innovative therapy targets the root cause of the infection and its associated symptoms, providing an effective monotherapy or complement to existing treatments. This enables healthcare professionals to manage H. pylori infections more efficiently.
Lant Medical
Seed Round in 2025
Lant Medical is a health technology company specializing in the development of non-antibiotic treatments for Helicobacter pylori (H. pylori) infections. Their innovative therapy targets the root cause of the infection and its associated symptoms, providing an effective monotherapy or complement to existing treatments. This enables healthcare professionals to manage H. pylori infections more efficiently.
Circadacare
Grant in 2025
Circadacare is a health technology company focused on enhancing the quality of life for older adults through innovative solutions in care environments. The company specializes in developing integrated systems that combine lighting, sensors, and software technology to synchronize the day-night cycle for residents, thereby improving their overall well-being. By translating scientific principles into practical applications, Circadacare aims to create care home lighting services that not only benefit the residents but also support staff efficiency. The solutions provided by Circadacare are designed to operate seamlessly, requiring minimal training for staff, while delivering both care outcome improvements for older adults and cost benefits for operators of nursing homes, care villages, and dementia care centers.
EnrichMyCare
Grant in 2025
EnrichMyCare is a technology company that specializes in developing a personal health platform. This platform aims to centralize and streamline care coordination, particularly for children, by improving communication among families, healthcare providers, social care services, and educators. It enables instant sharing of records and remote monitoring of the child's welfare, simplifying the complex process of managing care. The company's solutions help to accelerate care, enhance patient monitoring and engagement, prevent disabilities, and ultimately reduce healthcare costs.
Mulder
Grant in 2025
Mulder specializes in blockchain-based traceability solutions for the medical device industry. It develops a network platform that offers real-time visibility and traceability across the entire supply chain, from raw material sourcing to patient application. This enables healthcare providers and manufacturers to verify device provenance, ensure compliance, and enhance patient safety.
Axial3D
Venture Round in 2024
Axial3D specializes in 3D printing technology for healthcare, focusing on creating precise, patient-specific anatomical models derived from CT and MRI scan data. By providing a unique Online Ordering Portal, they enable clinicians to securely upload scans, allowing Axial3D's expert team to generate accurate physical models of patients' anatomy. These 3D printed models enhance the understanding of medical abnormalities, promote innovative surgical techniques, and ultimately improve surgical outcomes. The company's approach bridges the gap between technology and medicine, empowering surgeons and medical practitioners to effectively plan and rehearse complex procedures, thereby advancing the standards and efficiency of surgical interventions.
MediMusic
Grant in 2024
MediMusic is a health technology company that focuses on developing a medical technology platform aimed at alleviating pain, anxiety, and stress through the power of music. The platform leverages artificial intelligence to generate personalized playlists tailored to individual patient needs. By using soothing music, MediMusic's solution aims to lower heart rates and stimulate the vagus nerve, promoting a positive physiological response. This innovative approach not only helps in managing stress and anxiety but also enhances the effectiveness of pain medication, offering a holistic treatment option for patients dealing with various health challenges, including dementia and anxiety-related disorders.
LaennecAI
Grant in 2024
LaennecAI is a clinical AI company specializing in chronic disease management solutions. It has developed a medical device, a digital stethoscope, which transforms modern smartphones into powerful diagnostic tools. The company's technology enables precise monitoring and analysis of respiratory and cardiac sounds, facilitating telemedicine, remote patient monitoring, and virtual wards. This ensures patients receive in-depth, reliable analysis and continuous care.
Reneural Technologies
Grant in 2024
The goal of Reneural is to use technology to revolutionize healthcare delivery by increasing its effectiveness, efficiency, and accessibility for both patients and physicians.
Mulder
Pre Seed Round in 2024
Mulder specializes in blockchain-based traceability solutions for the medical device industry. It develops a network platform that offers real-time visibility and traceability across the entire supply chain, from raw material sourcing to patient application. This enables healthcare providers and manufacturers to verify device provenance, ensure compliance, and enhance patient safety.
Myogenes
Grant in 2024
Myogenes provides psychiatric tests, heredity cancer tests, and mental health mind maps.
Kaydiar
Grant in 2024
Kaydiar is a medical device company focused on developing innovative, cost-effective solutions for wound care, particularly for pressure injuries. They specialize in offloading technology, creating products such as orthotic devices, bed mattresses, wheelchair cushions, and prosthetic sleeves to relieve pressure and promote healing.
Epitopea
Grant in 2024
Epitopea is a biotechnology company focused on developing innovative immunotherapies for cancer treatment by targeting a new class of tumor-specific antigens. The company employs a proprietary approach that combines immunopeptidomics, mass spectrometry, genomics, and bioinformatics to identify conserved, aberrantly expressed tumor-specific antigens hidden within cancer's non-coding DNA. This technology aims to create therapies that effectively eliminate malignant cells while minimizing damage to healthy tissue, thereby reducing side effects and providing lasting benefits for patients. Research conducted by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal has been instrumental in the discovery of these novel antigens, known as Cryptigen™ TSAs, which are shared among patients with the same cancer type.
ScubaTx
Grant in 2024
ScubaTx focuses on developing an organ preservation system that utilizes the Persufflation method, which is known for its effectiveness in preserving organs during transportation. By enhancing the condition of grafts during preservation, ScubaTx enables healthcare providers to expand the availability of viable organs for transplantation. The company aims to improve organ preservation practices through innovative software design, ultimately delivering significant cost savings to healthcare providers. This advancement not only enhances the quality of organ transplants but also contributes to increasing the overall supply of life-saving organs available to patients in need.
Theolytics
Grant in 2024
Theolytics Limited is a clinical-stage biotechnology company founded in 2017 and based in Oxford, United Kingdom. The company specializes in developing oncolytic viral therapies to combat cancer, utilizing a phenotypic screening platform that facilitates the discovery and development of effective, targeted treatment candidates. These therapies are designed for intravenous delivery and tailored to specific patient populations, aiming to provide innovative care options. In addition to advancing its internal pipeline of programs that address both solid and liquid tumors, Theolytics is also focused on forming strategic partnerships to enhance and expedite its pipeline development.
Lentitek
Grant in 2024
Lentitek is a biotechnology company focused on developing gene and gene-modified cell therapies, particularly aimed at treating cancer. The company is dedicated to enhancing the accessibility of innovative cures by increasing the yield of lentiviral vectors, which are critical for gene therapy applications. Lentitek employs a proprietary method that utilizes a novel promoter to significantly boost lentiviral production, potentially increasing yields by tenfold or more. This innovative approach not only improves the efficiency of lentivirus production but also aims to reduce overall production costs for healthcare providers, thereby facilitating broader availability of advanced therapeutic options for patients.
SynaptixBio
Grant in 2024
SynaptixBio is a biotechnology company focused on developing innovative therapies for severe leukodystrophies, a group of rare genetic disorders affecting the brain's white matter. The company aims to disrupt existing treatment practices by creating a therapy that addresses the root cause of these diseases, specifically targeting the mutated TUBB4a gene implicated in TUBB4a Leukodystrophy. By leveraging groundbreaking research, SynaptixBio is dedicated to providing potentially curative options for patients suffering from this acute subset of leukodystrophies. The company also maintains an online platform to engage with customers and address inquiries, ensuring transparency and accessibility of information about their advancements.
Siloton
Grant in 2024
Siloton is a medical device manufacturer focused on creating diagnostic imaging devices for ophthalmology. The company specializes in developing advanced portable optical coherence tomography devices designed to address challenges in eye care. Their hand-held sub-surface imaging technology allows for home-based scanning, providing users with the ability to monitor their eye health and contribute to the prevention of avoidable blindness.
Naitive
Grant in 2024
Naitive is a population health company focused on improving patient care through AI-enabled clinical pathways and medical device technology. The company develops software that employs artificial intelligence, clinical data, and digital interventions to enhance the identification, treatment, and coordination of care for chronic diseases. By leveraging advanced computational capabilities, Naitive aims to support clinicians in transforming patient care while simultaneously reducing costs, time, and the failure rates commonly associated with chronic disease management.
BoobyBiome
Grant in 2024
BoobyBiome is a company focused on improving infant health through microbiome research. It specializes in developing probiotic supplements specifically designed for infants with compromised microbiomes, particularly those born prematurely. By recreating the beneficial bacteria associated with breast milk, BoobyBiome aims to support healthy infant development. The company is also working on formula milk probiotics to create a substitute that closely resembles breast milk, allowing infants to receive the essential bacteria that contribute to their gut health and immune system.
Cumulus Neuroscience
Grant in 2024
Cumulus Neuroscience develops an AI-based digital biomarker platform to aid in the resolution of the most pressing healthcare challenges in neurodegeneration and psychiatry. Cumulus Neuroscience's platform is intended to provide the critical data and insight required for more rapid, robust, and cost-effective clinical trials that improve patient access to new therapies. The platform's novel insights change the future of clinical trials in brain disorders, allowing life-changing therapies to reach patients faster and more affordably.
ThirtyFiveBio
Grant in 2024
ThirtyFiveBio is a biotechnology agency focused on developing innovative protein modulators aimed at treating severe gastrointestinal diseases, which represent a significant unmet clinical need. The company specializes in genetically and pharmacologically validated modulators that facilitate a comprehensive drug discovery program. This program is designed to identify small-molecule modulators of specific proteins, with the potential to impact a wide range of digestive system malignancies. By targeting GPR35 signaling, ThirtyFiveBio's approach aims to provide therapeutic options that may help in preventing tumor growth associated with gastrointestinal cancers.
KYMIRA
Grant in 2024
KYMIRA is an e-commerce company specializing in smart garments and textiles designed to enhance athletic performance and overall well-being. The company develops innovative products that utilize compression fabric combined with infrared and sensor technology. These garments harness and recycle the energy generated by athletes, aiming to improve performance, address chronic health issues, reduce injury risks, and enhance sleep quality. Additionally, KYMIRA's products provide valuable data insights for both men and women, enabling sports enthusiasts to optimize their training and recovery processes.
LIfT BioSciences
Grant in 2024
LIfT BioSciences is a biotechnology company based in London, England, founded in 2016. The company specializes in a novel allogeneic innate immuno-cell therapy platform known as Neutrophil Only Leukocyte Infusion Therapy (N-LIfT). This platform enables the large-scale production of Immunomodulatory Alpha Neutrophils (IMANs) derived from induced pluripotent stem cells (iPSCs) for various therapeutic applications. LIfT BioSciences focuses on developing CAR neutrophil cell therapies that address the limitations of existing treatments for solid tumors. These therapies work by directly attacking tumors and indirectly enhancing the immune response, effectively transforming the tumor microenvironment to recruit additional immune cells for a more robust and lasting attack on the cancer. By employing proprietary enhancement media and genetic engineering, LIfT BioSciences aims to significantly increase the cancer-fighting capabilities of these engineered cells, potentially providing patients with greatly improved therapeutic outcomes.
Nami Surgical
Grant in 2024
Nami Surgical specializes in developing and providing advanced robotic surgery technology. Their core offering is ultrasonic surgical tools designed to enhance the current robotic-assisted surgery market. By simplifying and making procedures safer, they expand the use of robots in surgeries requiring ultrasonic devices, thereby improving clinical outcomes and patient care. Their solutions provide surgeons with intuitive, high-performance, and maneuverable instruments for complex surgical tasks.
MedicSen
Grant in 2024
Medicsen is a start-up focused on healthcare innovation, primarily through the development of advanced technology solutions. A notable project is GlycSen, a needle-free drug delivery device aimed at providing a painless treatment option for individuals with insulin-dependent diabetes. This device integrates data from continuous glucose meters and user-inputted information, utilizing a learning algorithm to facilitate real-time monitoring. It features a chatbot interface that allows patients to easily track their condition, enhancing their ability to manage diabetes effectively. Through these innovations, Medicsen aims to improve the quality of life for those living with chronic diseases.
SleepCogni
Grant in 2024
SleepCogni is focused on developing innovative sleep aid technology that facilitates a personalized wind-down process to enhance sleep quality. The company's device, activated manually, utilizes sensors worn on the user's index finger to monitor key physiological and behavioral indicators, including heart rate, mental alertness, skin temperature, and movement. By employing cognitive behavioral therapy through biofeedback—delivered via visual, auditory, and tactile cues—SleepCogni aims to help users relearn healthy sleep patterns. This approach is designed to assist individuals in overcoming insomnia and improving their overall sleep cycle, offering a tailored solution to address common sleep challenges.
Monument Therapeutics
Grant in 2024
Monument Therapeutics is a biotechnology company focused on developing innovative drugs for serious diseases affecting the central nervous system. The company employs proprietary digital biomarkers to enhance patient identification by reducing heterogeneity and targeting those with similar underlying neurobiological conditions. This approach allows researchers to concentrate on advancing treatments in areas with significant unmet medical needs within the field of neuroscience.
GaitQ
Grant in 2024
GaitQ Limited, founded in 2019 and based in Oxfordshire, United Kingdom, specializes in developing a medical device aimed at assisting individuals with Parkinson's disease in overcoming freezing of gait. The company's product, known as the GaitThaw device, is small and portable, designed to utilize clinically proven sensory cues. These cues facilitate the re-establishment of the connection between the brain and the body, enabling patients to walk more smoothly and confidently.
machineMD
Grant in 2024
machineMD is a medical device company based in Switzerland, with a subsidiary in Boston, that focuses on advancing the fields of neuroscience and ophthalmology. The company aims to enhance the measurement of brain function, striving for timely and accurate diagnoses of brain disorders. By collaborating with a global network of clinical and research partners, machineMD seeks to extend the diagnostic capabilities of specialized medical practitioners to primary and secondary care settings. Its innovative automated device replaces traditional, manual assessments of eye movements and pupillary function, allowing medical assistants to conduct faster and more objective examinations. This technology provides ophthalmologists and neurologists with reliable measurements, ultimately improving patient care in the diagnosis of neurological conditions.
Graphene Trace
Grant in 2024
Graphene Trace is a healthcare technology company specializing in the prevention of pressure ulcers. It develops a smart, pressure-sensing fabric that continuously monitors and alerts users and caregivers to potential pressure points, enabling timely repositioning and preventing the formation of ulcers. The fabric is ultra-thin, comfortable, and affordable, making it suitable for use in wheelchairs and hospitals.
Renude
Seed Round in 2024
Renude is a company that offers personalized skincare advice through advanced artificial intelligence technology. The business aims to make reliable and individualized consultations accessible to a broad audience by leveraging a team of dermatologists, formulation chemists, licensed aestheticians, data scientists, and machine learning engineers. Renude develops dermatologist-approved AI skin advisors that facilitate virtual consultations, allowing users to receive tailored skincare plans based on their specific skin goals, individual needs, preferences, budget, and lifestyle. Through this innovative approach, Renude seeks to empower individuals to achieve their skincare objectives effectively.
Cumulus Neuroscience
Grant in 2024
Cumulus Neuroscience develops an AI-based digital biomarker platform to aid in the resolution of the most pressing healthcare challenges in neurodegeneration and psychiatry. Cumulus Neuroscience's platform is intended to provide the critical data and insight required for more rapid, robust, and cost-effective clinical trials that improve patient access to new therapies. The platform's novel insights change the future of clinical trials in brain disorders, allowing life-changing therapies to reach patients faster and more affordably.
Presymptom Health
Grant in 2024
Presymptom Health is a medtech company that specializes in developing clinical decision support algorithms and diagnostic tests aimed at early illness detection. The company focuses on pre-symptomatic diagnostics, allowing for the identification of conditions such as sepsis up to three days before symptoms manifest. By enabling earlier intervention, Presymptom Health's innovations aim to enhance critical care outcomes and improve patient management. Through its portfolio of blood tests and algorithms, the company seeks to transform the way healthcare providers approach patient care, ultimately contributing to better health outcomes and potentially saving lives.
IXICO
Grant in 2024
IXICO plc, established in 1995 and headquartered in London, specializes in providing data analytics services to the global biopharmaceutical industry. The company focuses on the collection, analysis, management, and reporting of data generated during clinical studies, with a particular emphasis on neurological diseases. IXICO's key technologies include Assessa, a digital platform for clinical decision support, and TrialTracker, a comprehensive imaging service workflow management system. The company's end-to-end imaging services are primarily applied in the fields of Alzheimer's, Parkinson's, Huntington's, multiple sclerosis, cerebrovascular, and progressive supranuclear palsy diseases. IXICO's services are utilized to select patients for clinical trials, assess drug safety and efficacy, and for post-marketing surveillance. The company works with pharmaceutical companies, biotech firms, academia, and medical charities worldwide.
SolasCure
Grant in 2024
SolasCure Limited is a biotechnology company based in Wales, United Kingdom, focused on developing innovative solutions for patients with chronic wounds. Founded in 2017, the company is advancing its product Aurase, a hydrogel designed to facilitate wound debridement by removing dead, damaged, or infected tissue to enhance healing. Aurase incorporates a recombinant enzyme derived from maggots, leveraging biomimicry and evidence-based medicine to improve wound care outcomes. SolasCure aims to provide effective wound bed preparation across various healthcare settings, ultimately accelerating the healing process for individuals suffering from chronic wounds.
Cortirio
Grant in 2024
Cortirio specializes in the development of portable brain imaging technology aimed at diagnosing and monitoring traumatic brain injuries, which are a leading cause of death and disability among individuals under 40. The company's innovative portable scanners utilize near-infrared imaging with enhanced spatial resolution to deliver point-of-care medical imaging. This technology enables healthcare providers to access vital information throughout the clinical pathway, facilitating automatic analysis and data transfer. By providing timely and accurate diagnostic capabilities, Cortirio's devices empower clinicians to make quicker decisions, ultimately improving care for patients suffering from brain injuries and strokes.
SökerData
Grant in 2024
SökerData is a biotechnology company specializing in data analysis solutions for disease-related datasets. It has developed a data visualization platform designed to analyze biomarkers in clinical outcomes across different demographic groups. The platform offers tools for interpreting large datasets, supporting early drug discovery, and aiding researchers in understanding the impact of biomarkers on diverse populations, thereby facilitating informed decision-making and advancing disease outcome understanding.
Concr
Grant in 2024
Concr is a techbio company focused on enhancing cancer treatment by predicting patient responses to various therapies. Utilizing methods from astrophysics, Concr's innovative approach allows for iterative learning from diverse data sources throughout a drug's clinical journey, resulting in accurate multi-modal tumor models without relying on extensive data sets. Its cloud-native platform, FarrSight®, enables researchers to simulate clinical trials, predict therapeutic responses and biomarkers, and conduct standard bioinformatics analyses. This technology aims to identify optimal treatments for individual patients, reduce treatment resistance, and facilitate personalized cancer management. Headquartered in London with a subsidiary in Brisbane, Australia, Concr is backed by several investors, including the University of Cambridge Enterprise and Oncology Ventures.
Lucida Medical
Grant in 2024
Lucida Medical is a developer of healthcare technology that utilizes artificial intelligence to enhance the detection and diagnosis of cancer. The company has created software that supports the analysis of MRI scans, focusing on applications for cancer diagnosis, screening, and management. Its flagship product, Pi, is designed specifically for the diagnosis of prostate cancer through multiparametric or diffusion MRI and has received CE marking as a medical device. By integrating imaging and multi-omics biomarkers, Lucida Medical aims to provide clinicians with tools that make cancer detection more accurate, accessible, cost-effective, and rapid. The company is interested in collaborating with investors and hospital partners who share its commitment to early cancer detection.
Cyted Health
Grant in 2023
Cyted Health specializes in developing a digital diagnostic infrastructure aimed at the early detection of diseases, particularly cancer. By leveraging artificial intelligence and innovative biomarkers, Cyted's platform enhances clinical insights and facilitates improved patient outcomes. The company's mission is to transform diagnostic methodologies, focusing on prevention rather than treatment, thereby contributing to a healthcare landscape where diseases are identified and addressed at their earliest stages.
Holly Health
Seed Round in 2023
Holly Health is a digital health coaching application that assists individuals in transforming their health intentions into actionable daily habits for improved mental and physical wellbeing. Utilizing proprietary AI systems, the service mimics the support of a human health coach, offering personalized guidance to users. The application features tools such as habit reminders, tailored health content, and progress tracking, all aimed at helping users establish and maintain healthier routines. Recognized as one of the top health apps for weight management, stress reduction, wellness, and sleep, Holly Health achieved a notable evaluation score of 89% from ORCHA, a leading health app assessment organization. Launched internationally in Summer 2021, the company aims to support five million individuals by 2025 and is actively partnering with primary care practices in the UK, having established over 100 collaborations to date.
Holly Health
Grant in 2023
Holly Health is a digital health coaching application that assists individuals in transforming their health intentions into actionable daily habits for improved mental and physical wellbeing. Utilizing proprietary AI systems, the service mimics the support of a human health coach, offering personalized guidance to users. The application features tools such as habit reminders, tailored health content, and progress tracking, all aimed at helping users establish and maintain healthier routines. Recognized as one of the top health apps for weight management, stress reduction, wellness, and sleep, Holly Health achieved a notable evaluation score of 89% from ORCHA, a leading health app assessment organization. Launched internationally in Summer 2021, the company aims to support five million individuals by 2025 and is actively partnering with primary care practices in the UK, having established over 100 collaborations to date.
Holly Health
Seed Round in 2023
At Holly Health, we are transforming the way individuals approach mental and physical well-being. Founded in 2020, we’ve developed an AI-powered digital health coach that empowers users to turn their health intentions into clear, actionable steps. Our personalized, compassionate service is designed to fit seamlessly into everyday life, supporting long-term, sustainable health changes. Using proprietary AI systems, Holly Health mimics the guidance of a human health coach, offering support in areas such as weight management, stress reduction, wellness, and sleep. We are proud to be ranked among the top 3 health apps by ORCHA, the world’s leading health app evaluation body, with a score of 89%. Since our international launch in 2021, Holly Health has been on a mission to improve the lives of 5 million people by 2025. We are rolling out partnerships with over 100 primary care practices in the UK, helping healthcare professionals support patients with preventative health measures and ongoing well-being. At Holly Health, we believe that health is not a destination but a journey. By offering tailored, science-backed coaching, we make it easier for people to prioritize their well-being every day. Join us as we revolutionize digital health coaching for the modern world.
Bioliberty
Grant in 2023
Bioliberty is a medtech start-up focused on creating innovative rehabilitation solutions for individuals with degenerative and traumatic conditions. The company develops robotic gloves that leverage artificial intelligence to facilitate muscle recovery. By utilizing assistive robotics and rehabilitative devices, Bioliberty aims to support patients suffering from various ailments, including stroke, motor neuron disease, multiple sclerosis, rheumatoid arthritis, and osteoarthritis. These devices are designed to assist users in overcoming hand weakness, enabling them to perform daily tasks more effectively and enhance their hand strength, ultimately promoting greater independence and comfort in their own homes.
CellRev
Grant in 2023
CellRev is a biotechnology company specializing in innovative bioprocessing technologies aimed at improving cell manufacturing for various applications, including cultured meat, cell therapy, and biologics. The company's proprietary technology enables a shift from traditional batch processing to continuous processing of adherent cells, significantly enhancing yield while reducing operating costs and capital expenditures. CellRev's unique cell detachment process, combined with a specially designed bioprocess, addresses critical challenges in manufacturing, such as cell aggregation, clumping, and detachment. This approach allows cell-based vaccine and therapy developers to streamline their production processes, eliminate serum usage, and overcome significant bottlenecks in the industry.
BelleVie
Grant in 2023
BelleVie is a provider of personal care services aimed at supporting individuals in their daily lives while enabling them to maintain their independence. The company offers a range of services, including personal care, meal preparation, home assistance, social engagement, and specialized care. BelleVie operates with a unique model of self-managing teams, inspired by the successful Buurtzorg approach from the Netherlands, which emphasizes fulfilling careers in care and fosters meaningful relationships within the care ecosystem. The company utilizes its proprietary Wellbeing OS technology platform to facilitate its operations, funded through a monthly subscription model. BelleVie’s vision focuses on creating a society where every individual is valued and supported, ensuring that care providers and recipients alike benefit from reciprocal and enriching interactions.
SynaptixBio
Grant in 2023
SynaptixBio is a biotechnology company focused on developing innovative therapies for severe leukodystrophies, a group of rare genetic disorders affecting the brain's white matter. The company aims to disrupt existing treatment practices by creating a therapy that addresses the root cause of these diseases, specifically targeting the mutated TUBB4a gene implicated in TUBB4a Leukodystrophy. By leveraging groundbreaking research, SynaptixBio is dedicated to providing potentially curative options for patients suffering from this acute subset of leukodystrophies. The company also maintains an online platform to engage with customers and address inquiries, ensuring transparency and accessibility of information about their advancements.
Spirecut
Grant in 2023
Spirecut is a MedTech company specializing in innovative surgical instruments designed for the treatment of carpal tunnel syndrome and trigger finger. The company has developed a patented technique for ultrasound-guided surgery that eliminates the need for skin incisions, resulting in no post-operative wounds. This approach allows patients to resume daily activities immediately without the need for dressings or coverings on the operated area. Spirecut's instruments represent a significant advancement over traditional methods, improving upon the simple needles typically used by surgeons and radiologists. The enhanced design facilitates the safe release of thickened tissue and aids in preoperative sonographic tracking, ultimately enabling surgeons to achieve better surgical outcomes and accelerating patient recovery.
Brainomix
Grant in 2023
Brainomix Limited, established in 2010 as a spin-out from the University of Oxford, develops advanced imaging biomarkers and software solutions aimed at enhancing clinical decision-making for neurological and cerebrovascular disorders. The company's flagship product, e-Stroke, employs state-of-the-art artificial intelligence algorithms to automate the interpretation of brain scans, specifically for acute ischemic stroke patients. This tool assists physicians in identifying and quantifying early stroke damage, thereby facilitating timely and informed treatment decisions. In addition to e-Stroke, Brainomix offers other software products such as e-ASPECTS, which automates the Alberta Stroke Program Early CT Score, and e-CTA, which standardizes the assessment of large vessel occlusion locations. These innovative solutions address the critical need for rapid and consistent evaluations of brain CT scans, ultimately optimizing patient outcomes and ensuring that stroke patients receive appropriate care in a timely manner. The company is headquartered in Oxford, United Kingdom.
Pathios Therapeutics
Grant in 2023
Pathios Therapeutics Limited is an early-stage drug discovery company based in Oxford, United Kingdom, founded in 2017. The company is dedicated to developing therapies for autoimmune diseases and cancer, focusing on small molecule inhibitors that target the pH-sensing G protein-coupled receptor GPR65. These inhibitors are designed to mitigate the immunosuppressive polarization of immune cells, such as tumor-associated macrophages, which is often stimulated by the acidic microenvironment present in tumors. By employing a rigorous scientific approach that includes insights from human genetics and advanced cellular immunology, Pathios aims to generate novel therapeutics that can address advanced solid tumors and other significant medical needs in immuno-oncology.
ThirtyFiveBio
Grant in 2023
ThirtyFiveBio is a biotechnology agency focused on developing innovative protein modulators aimed at treating severe gastrointestinal diseases, which represent a significant unmet clinical need. The company specializes in genetically and pharmacologically validated modulators that facilitate a comprehensive drug discovery program. This program is designed to identify small-molecule modulators of specific proteins, with the potential to impact a wide range of digestive system malignancies. By targeting GPR35 signaling, ThirtyFiveBio's approach aims to provide therapeutic options that may help in preventing tumor growth associated with gastrointestinal cancers.
Stablepharma
Grant in 2023
Stablepharma Ltd specializes in developing innovative processes for vaccine stabilization, focusing on its technology platform, StablevaX™, which transforms existing approved vaccines, therapeutics, and diagnostics into thermostable products that do not require refrigeration. This advancement addresses the global challenges associated with cold chain logistics, allowing for efficient and waste-free vaccine delivery. The company has identified up to 60 vaccine candidates suitable for its technology and collaborates with global vaccine manufacturers, academic institutions, and non-governmental organizations to enhance its pipeline of thermostable products. Founded in 2012 and based in Bath, United Kingdom, Stablepharma aims to reduce costs and carbon emissions while expanding access to vaccines for both children and adults.
Jude
Grant in 2023
Jude is a healthcare company focused on addressing bladder health issues and raising awareness about incontinence. The organization offers a range of services that include expert advice from medical professionals through social media, virtual seminars, and private chat options. Additionally, Jude provides health products designed to assist individuals in managing their bladder health effectively. By combining educational resources with accessible support, Jude aims to empower individuals to understand their medical conditions and pursue solutions for a leak-free life.
AstronauTx
Grant in 2023
AstronauTx is a biotechnology company focused on developing treatments for Alzheimer's disease and other neurodegenerative conditions. The company aims to restore the normal functioning of astrocytes, which are crucial cells in the brain that support neuronal activity, metabolism, and the integrity of the blood-brain barrier. In conditions such as dementia, astrocytes can become dysfunctional, leading to neurotoxicity and exacerbating disease progression. By targeting astrocyte homeostasis, AstronauTx seeks to enable healthcare professionals to effectively address the underlying mechanisms of neurotoxicity associated with these diseases, ultimately improving treatment options for patients suffering from dementia and related disorders.
TherageniX
Grant in 2023
TherageniX specializes in gene therapy for tissue regeneration, focusing on orthopedic applications. The company's patented technology uses a non-viral delivery system to introduce specific genes, such as VEGF and BMP, into autologous bone marrow cells, enhancing their regenerative capacity. This process aids in tissue repair and regeneration, improving functional outcomes and reducing donor site trauma for patients with diseases, injuries, or age-related tissue damage.
NK:IO
Grant in 2023
NK:IO is a biotechnology company focused on advancing natural killer cell-mediated immunotherapy, particularly in the realm of cancer treatment. The company specializes in developing innovative cell therapies and small molecule therapeutics designed to enhance the effectiveness of cancer targeting for physicians. By leveraging cutting-edge research and technology, NK:IO aims to improve treatment outcomes for patients facing cancer.
Corryn Biotechnologies
Grant in 2023
Corryn Biotechnologies is a biotechnology company focused on innovating wound care solutions through its Heals device, which offers a contactless method for treating chronic and complex wounds. The company has developed advanced applicators that utilize electrical voltages to extrude fine fibers from various fluids, creating wound dressings that can be made from synthetic or natural materials. These dressings can be enhanced with or without active ingredients and are designed to deposit non-woven meshes for effective Advanced Tissue Repair (ATR). Through this technology, Corryn aims to improve the management and healing of chronic wounds, providing a novel approach to wound dressing.
Damibu
Grant in 2023
Damibu Ltd is a technology company specialising in innovative digital solutions, particularly for healthcare and public sector organisations. They focus on creating platforms that simplify content management and distribution, enhancing communication efficiency. Notably, their product Damibu Feeds aids NHS groups in the UK by automating content sharing among GP surgeries, saving time and resources. Their approach emphasises user-friendly designs and interoperability, ensuring seamless integration with existing systems. Damibu's commitment to improving digital health communication is evident in their solutions, which aim to streamline processes, ensure content accuracy, and enhance patient engagement through reliable and accessible information dissemination.
Kalium Health
Grant in 2023
Kalium Health Ltd is a company focused on improving kidney care through innovative medical technology. Based in Cambridge, United Kingdom, it designs and manufactures a finger-prick blood test specifically for measuring blood potassium concentration. This test aims to facilitate early treatment for patients, reducing the complications and costs associated with traditional testing methods. By leveraging advanced electrolyte sensing technology, Kalium Health provides patients with accurate, real-time data essential for managing cardiorenal diseases. The company’s first product addresses a significant risk in kidney disease, a condition that imposes substantial financial burdens on healthcare systems. With a clear regulatory pathway and a targeted market strategy, Kalium Health is poised to transform patient care and enhance outcomes for millions affected by kidney disease.
Autolomous
Grant in 2023
Autolomous Ltd, founded in 2019 and based in Mayfair, United Kingdom, specializes in developing software solutions for manufacturers of cell and gene therapies. Its flagship platform, autoloMATE®, is a cloud-native system that provides comprehensive support for Advanced Therapies and Vector manufacturing processes. The software facilitates the scheduling of patient cell collections, the transport of these cells to production sites, and the tracking of manufacturing processes to ensure compliance with regulatory standards. It also supports the legal release and timely delivery of patient-specific medicines. The highly configurable platform allows clients to customize workflows and integrates seamlessly with existing systems. Autolomous emphasizes data security by utilizing blockchain technology to maintain the integrity of manufacturing data. The company adheres to strict regulatory guidelines and has achieved several ISO certifications, reflecting its commitment to quality management and environmental standards.
Mumbli
Grant in 2023
Mumbli is a company focused on enhancing hearing experiences through innovative technology. It develops a hearing wellness platform that integrates wireless sound sensors to make venues more accessible for individuals who are hard of hearing or sensitive to noise. Mumbli's IoT system continuously monitors and reports on sound performance in real-time, allowing venue operators to maintain optimal sound levels. This platform not only certifies venues based on quality of conversation and healthy noise levels but also provides valuable data to support decision-making and address customer concerns. By improving the auditory environment, Mumbli aims to foster inclusivity and enhance the overall experience in various settings.
Change My Face
Grant in 2023
Change My Face is an AI-powered face-changing technology used in healthcare, finance and skincare.
Juniver
Grant in 2023
Juniver offers specialized care and support for individuals recovering from eating disorders through a neuroscience-based recovery program. The company provides an on-demand platform that includes practical tools and habit-formation principles, aimed at helping users manage cravings and urges. By fostering a supportive community, Juniver facilitates long-term recovery, addressing the complexities of disordered eating in a comprehensive manner.
CalmBrain
Grant in 2023
CalmBrain is a digital platform that provides psychological intervention for schools to assist students in managing their mental health, including anxiety, stress, and trauma.
The Allergy Team
Grant in 2023
The Allergy Team assists families, companies, and educational institutions in managing food allergies.
Boost Innovations
Grant in 2023
Boost Innovations focuses on developing products specifically for women, with a particular emphasis on enhancing comfort and confidence. The company specializes in creating breast prostheses designed to provide both security and usability for users, especially those who have undergone surgery. Their innovative breast forms are crafted to remain secure within post-surgery underwear and are suitable for various activities, including swimming and exercising. By prioritizing breathability and functionality, Boost Innovations aims to meet the unique needs of its customers, ensuring they feel comfortable and confident in their daily lives.
Kids Speech Labs
Grant in 2023
Kids Speech Labs is a digital health company focused on transforming the delivery of speech and language therapy services through innovative technology. The company develops AI-driven solutions that include remote monitoring tools and interactive speech and language games. These resources empower parents to track their children's speech development effectively. By leveraging artificial intelligence, Kids Speech Labs aims to enhance the therapeutic experience, making it more accessible and engaging for children and their families.
Zeal Lifestyle
Grant in 2023
Life with Zeal a lifestyle brand that is revolutionizing the assisted living market.
Orthonika
Grant in 2023
Orthonika Limited, established in 2014 and based in London, United Kingdom, specializes in the development and manufacturing of MenisciKnit, an anatomical meniscus replacement designed to address severe meniscus injuries. These injuries can significantly impair mobility and lead to complications such as osteoarthritis and the need for knee arthroplasty. Current treatment options, including partial meniscectomy and allograft transplantation, often fall short, leaving a significant unmet need in the market. MenisciKnit employs a unique fiber-reinforced material structure that closely mimics the natural meniscus, aiming to restore proper knee biomechanics. This innovative approach not only provides a solution for those with severe meniscus damage but also supports patients in resuming active lifestyles and offers a comprehensive alternative to traditional knee-related treatments.
Tycho Medlink
Grant in 2023
Tycho Medlink is to help people achieve new levels of rehabilitation through digital therapy.
XR Therapeutics
Grant in 2023
XR Therapeutics is a start-up company that originated from over a decade of academic research at Newcastle University. The company operates a healthcare services platform designed to assist individuals with anxiety and phobias through innovative therapies. XR Therapeutics offers a unique virtual reality treatment that integrates traditional Cognitive Behaviour Therapy with immersive virtual environments. This approach allows practitioners to create tailored scenes that meet the specific needs of patients, facilitating effective treatment for both adults and children experiencing mental health issues.
InsideOut
Grant in 2023
InsideOut is a London-based company that focuses on mental health care and well-being support. It has developed a therapy platform aimed at reducing social stigma surrounding mental health and fostering open conversations about the subject. The platform provides continuous therapy support through an online application, which employs an intelligent matching system to connect users with suitable therapists. This approach enables individuals to maintain positive mental well-being by accessing tailored therapeutic resources and support.
SyncVR Medical
Grant in 2023
SyncVR Medical is dedicated to enhancing healthcare through virtual and augmented reality (VR/AR) solutions. As the largest XR platform for healthcare in Europe and the UK, the company serves over 125 healthcare institutions across several countries, including the Netherlands, Germany, Denmark, Sweden, Belgium, the UK, and France. SyncVR Medical's platform offers a range of applications designed to support patient care, alleviate pain and anxiety, and improve treatment outcomes based on scientific research. Additionally, more than 25 third-party developers contribute to the platform, providing access to a broader customer base in the healthcare sector. SyncVR Medical aims to establish itself as the leading XR platform in the top five European healthcare markets by 2025.
Rescape Innovation
Grant in 2023
Rescape Innovation Limited, based in Cardiff, United Kingdom, specializes in the design and manufacture of healthcare equipment focused on enhancing patient experiences. Incorporated in 2017, the company is at the forefront of using virtual reality technology to address various healthcare challenges, including pain management, anxiety reduction, and communication support. Through its innovative virtual reality distraction therapy, Rescape Innovation aims to improve patient outcomes and overall well-being in clinical settings.
Care Reality
Grant in 2023
Care Reality are a hybrid of EdTech and HealthTech building a new reality for learning.
Neu Health
Grant in 2023
Neu Health develops a smartphone-based clinical platform designed to deliver personalized care for individuals with Parkinson's disease and dementia. Utilizing cutting-edge digital technologies and artificial intelligence, the platform monitors and interprets digital indicators of clinically relevant symptoms. This approach aims to enhance condition management, alleviate the workload on clinicians, and ultimately improve patient outcomes. By enabling clinicians and caregivers to provide more efficient and effective care, Neu Health addresses the growing challenges faced by those managing these complex neurological conditions.
ScubaTx
Grant in 2023
ScubaTx focuses on developing an organ preservation system that utilizes the Persufflation method, which is known for its effectiveness in preserving organs during transportation. By enhancing the condition of grafts during preservation, ScubaTx enables healthcare providers to expand the availability of viable organs for transplantation. The company aims to improve organ preservation practices through innovative software design, ultimately delivering significant cost savings to healthcare providers. This advancement not only enhances the quality of organ transplants but also contributes to increasing the overall supply of life-saving organs available to patients in need.
Lindus Health
Grant in 2023
Lindus Health is a clinical research organization focused on delivering comprehensive clinical trial services for health and biotech companies. The company offers a range of solutions, including ethics and IRB submission, trial monitoring, data management, biostatistics, regulatory support, and payer affairs. By utilizing a proprietary software platform, Lindus Health automates various aspects of the clinical trial workflow, which streamlines operations and minimizes manual inefficiencies. This platform also facilitates access to electronic health records, enhancing patient recruitment and clinical data capture. Furthermore, Lindus Health leverages real-world patient data to improve trial design and execution, ultimately aiming to accelerate the clinical trial process while reducing risks and costs associated with trial failures.
Senisca
Grant in 2023
Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.
Vitarka Therapeutics
Grant in 2023
Vitarka Therapeutics is a London-based company focused on developing medical technologies and solutions for various types of cancer. The company has created a targeted non-viral delivery platform aimed at intracellular targets in oncology, neuroscience, and neurodegeneration. This innovative platform works by activating the immune system and normalizing tumor vasculature, significantly improving outcomes for late-stage patients suffering from lung, colon, breast, and other cancers. By utilizing re-engineered pore-forming proteins for cell-specific targeting and facilitating the endosomal release of therapeutic cargo, Vitarka Therapeutics aims to provide cancer patients with renewed hope and the potential to lead more normal lives.
Calla Lily Clinical Care
Grant in 2023
Calla Lily Clinical Care is a women’s health-focused B-Corp that has created the proprietary Callavid® platform for intravaginal drug delivery. The company targets fertility and pregnancy with its innovative drug-device combination product aimed at preventing miscarriages and providing support during the luteal phase of In Vitro Fertilization (IVF). Additionally, Callavid® is designed to deliver live biotherapeutics to address recurrent Bacterial Vaginosis, thereby reducing antibiotic use and mitigating the spread of antimicrobial resistance. Other applications include hormone replacement therapy for menopause and the Lilyvid™ device, which facilitates advanced medical sample collection for biomarker-based diagnostics related to endometriosis and various other health conditions. The technology behind these devices has been recognized as a TIME Magazine Best Invention of the Year.
QV Bioelectronics
Grant in 2023
QV Bioelectronics is focused on improving the lives of brain tumor patients through its innovative electric field therapy implant, GRACE. Developed in collaboration with leading neurosurgeons in the UK, GRACE aims to extend the life expectancy of glioblastoma patients, a group historically faced with limited treatment options and poor survival rates. Recognizing the urgent need for effective therapies, co-founders Dr. Richard Fu and Dr. Chris Bullock created a solution to address both the clinical and quality of life challenges faced by patients. The company has garnered nearly $1 million in funding from UK institutions, including Innovate UK, and over $1 million in equity funding from international life science investors. With a multidisciplinary team based in Alderley Park, Cheshire, QV Bioelectronics is dedicated to advancing GRACE from research to clinical application, utilizing cutting-edge materials science to enhance treatment outcomes for patients.
Doctoria
Grant in 2023
Doctoria is a virtual healthcare platform to enable doctors and patients to connect better.
Syndi
Grant in 2023
Syndi is a digital health platform that focuses on enhancing health outcomes through technology and research, initially targeting mental health. The platform employs machine learning and digital phenotyping to provide personalized and immediate care by utilizing moment-by-moment passive smartphone data collection. This approach allows for effective and accessible support tailored to individual needs. Syndi's services aim to improve the treatment of invisible disabilities by facilitating connections between patients and healthcare providers, while also measuring the effectiveness of its applications and digital services. Through its innovative solutions, Syndi seeks to transform the way people access and engage with healthcare.
LightOx
Grant in 2023
Lightox specializes in developing advanced molecular tools for imaging, therapeutics, and assay development, focusing on innovative cancer treatments. The company has created a range of light-activated drug compounds designed to selectively target and eliminate tumor cells while minimizing harm to surrounding healthy tissue. Their unique fluorescent probes are smaller than any other products currently available, allowing for versatile applications in research and clinical settings. These probes can function as freely-moving agents that easily integrate into cells, or they can be customized with flexible linkers to meet specific research requirements. Lightox aims to enhance patient outcomes by providing more efficient cancer treatment options.
PatientMpower
Grant in 2023
PatientMpower specializes in remote monitoring solutions aimed at patients with chronic diseases, particularly those with respiratory conditions. The company develops applications that integrate with devices such as spirometers and pulse oximeters, allowing patients to conduct measurements at home. These devices connect to a smartphone application, which transmits real-time data to healthcare providers. This integration supports healthcare professionals in delivering high-quality care and enhances patient outcomes by facilitating continuous monitoring. Additionally, the data collected contributes to research efforts aimed at improving treatment options for chronic conditions.
Myma Medical
Grant in 2023
Myma Medical is a bright, cutting-edge start-up with a model to greatly improve the experiences of people who are having fertility issues.
Fly Mama
Grant in 2023
FLY Mama is an online membership platform that provides trauma-informed integrated healthcare solutions for pre and postpartum well-being. The platform is designed to empower mothers by addressing their mental, emotional, and physical health needs during fertility journeys, pregnancy, and the aftermath of perinatal trauma and loss. FLY Mama aims to launch an employee benefit program to support women through these critical stages, ensuring they receive professional and safe care. By focusing on comprehensive support, the company seeks to enable women to feel confident, happy, and empowered throughout their motherhood journey.
KYMIRA
Grant in 2023
KYMIRA is an e-commerce company specializing in smart garments and textiles designed to enhance athletic performance and overall well-being. The company develops innovative products that utilize compression fabric combined with infrared and sensor technology. These garments harness and recycle the energy generated by athletes, aiming to improve performance, address chronic health issues, reduce injury risks, and enhance sleep quality. Additionally, KYMIRA's products provide valuable data insights for both men and women, enabling sports enthusiasts to optimize their training and recovery processes.
BelleVie
Grant in 2022
BelleVie is a provider of personal care services aimed at supporting individuals in their daily lives while enabling them to maintain their independence. The company offers a range of services, including personal care, meal preparation, home assistance, social engagement, and specialized care. BelleVie operates with a unique model of self-managing teams, inspired by the successful Buurtzorg approach from the Netherlands, which emphasizes fulfilling careers in care and fosters meaningful relationships within the care ecosystem. The company utilizes its proprietary Wellbeing OS technology platform to facilitate its operations, funded through a monthly subscription model. BelleVie’s vision focuses on creating a society where every individual is valued and supported, ensuring that care providers and recipients alike benefit from reciprocal and enriching interactions.
Fallouh Healthcare
Grant in 2022
Fallouh Healthcare specializes in the development and manufacturing of medical devices and AI-based software for cardiac surgery. Their products aim to enhance patient safety and streamline surgical workflows. Key offerings include systems for monitoring and protecting the heart during surgery, and AI-driven tools to detect and prevent complications like tamponade.
Healthera
Debt Financing in 2022
Healthera Ltd., established in 2015 and headquartered in Cambridge, UK, specializes in developing digital health solutions. Its flagship product, Healthera, is a pharmacy-integrated medication management app that offers automatic prescription reminders, smart labelling, scheduling, health condition tracking, and professional advice from pharmacists. Additionally, Healthera operates a healthcare marketplace that connects patients with local pharmacies and GPs, enabling faster medicine delivery and personalized care. The company partners with over 1000 pharmacies and Clinical Commissioning Groups (CCGs) across the UK, reaching over 20 million people. Its technology is accredited by NHS Digital and aims to improve prescribing efficiency, patient experience, and reduce wastage within the NHS.
NIQS Technology
Grant in 2022
NIQS Tech is a spin-out from the University of Leeds that specializes in quantum technology, specifically focusing on non-invasive glucose monitoring for diabetes management. The company has developed a patented wearable monitor that utilizes nano-engineered glass to continuously and accurately measure glucose levels without the need for needles or blood. This user-friendly technology aims to provide actionable insights that empower individuals living with diabetes to manage their condition effectively and improve their overall quality of life. By eliminating the need for traditional glucose management methods, NIQS Tech seeks to reduce the risk of diabetes-related complications and enhance the well-being of its users.
Emm
Seed Round in 2022
Emm is focused on creating innovative consumer health tools that empower individuals to manage their health effectively. The company has developed a wearable device aimed at enhancing reproductive health by providing users with biometric data that offers actionable insights into their unique reproductive profiles. This technology enables users and their healthcare providers to identify potential health issues and optimize reproductive health outcomes, thereby improving the overall quality of life. Emm's approach combines advanced technology with specialized knowledge to enhance personal health management.
Brainstem Digital Health
Grant in 2022
Brainstem is a DePIN to collect and utilise wearable health data. Our mission is to revolutionize healthcare and improve lives through remote screening, ongoing monitoring, digital treatment alternatives, and tools to share data with practitioners, researchers, and others. We are committed to building a network of users who are willing to share their data and embracing collaboration with smart minds to speed innovation. With our vision of being a 24/7 virtual health assistant specializing in sleep, mental, cardio, and neuro health, we are at the forefront of digital health.
National Biofilms Innovation Centre
Grant in 2022
The National Biofilms Innovation Centre (NBIC) serves as a collaborative hub uniting academia, industry, government, and public policy to address the challenges posed by biofilms, which significantly impact global economic activity across sectors such as food, health, shipping, clean water, and energy. Supported by funding from the BBSRC, Innovate UK, and Hartree Centre, NBIC's mission focuses on fostering a network for research and innovation that catalyzes partnerships with industry to drive breakthrough innovations. The Centre facilitates the exploration of unmet needs and the exchange of ideas through various initiatives, including roadmaps, workshops, and conferences. Additionally, NBIC is dedicated to nurturing the next generation of scientists through PhD and Post-Doc programs, alongside entrepreneurial training, aimed at enhancing their expertise and understanding of the commercial landscape while promoting the creation of new start-ups.
Ascentys
Grant in 2022
Ascentys provides digital health business services.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.